Topic

Zanzalintinib (XL092) [investigational]

A collection of 39 issues

Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in Michigan: Clinical Trials, Compassionate Use, and Appeals Guide 2025

Answer Box: Your Path to Zanzalintinib Access Zanzalintinib (XL092) is an investigational drug not yet FDA-approved. UnitedHealthcare typically denies coverage outside clinical trials. Your fastest path: 1) Search active trials at ClinicalTrials.gov for "XL092" or contact your oncologist about STELLAR program studies, 2) If trial-ineligible, pursue Exelixis

How to Get Zanzalintinib (XL092) Covered by Aetna CVS Health in Washington: Clinical Trial Access, Appeals & Timelines

Answer Box: Getting Zanzalintinib (XL092) Covered by Aetna CVS Health in Washington Zanzalintinib (XL092) is an investigational drug not FDA-approved, so standard Aetna CVS Health coverage is typically denied. The fastest path is through clinical trials (drug provided free by Exelixis) or compassionate use programs where Aetna may cover routine

How to Get Zanzalintinib (XL092) Covered by Cigna in Georgia: Clinical Trial Access, Compassionate Use, and Appeals Guide

Answer Box: Getting Zanzalintinib (XL092) Approved by Cigna in Georgia Zanzalintinib (XL092) is investigational and not on Cigna formularies, but you have three paths: (1) Clinical trial enrollment where Cigna covers routine care costs while Exelixis provides the drug, (2) Compassionate use through Exelixis Medical Affairs with prior authorization for

Work With Your Doctor to Get Zanzalintinib (XL092) Approved by UnitedHealthcare in Virginia: Clinical Evidence, Appeals, and Expanded Access

Answer Box: Getting Started Zanzalintinib (XL092) is investigational and typically requires expanded access through Exelixis rather than insurance coverage. However, if your oncologist believes insurance coverage for routine care costs is appropriate, here's your fastest path: 1. Visit prep: Gather your complete treatment history, molecular testing results, and

Getting Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Appeals Guide with Forms and External Review

Answer Box: Getting Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Pennsylvania Zanzalintinib (XL092) is an investigational multi-target TKI from Exelixis with no FDA approval, making Blue Cross Blue Shield coverage challenging but not impossible. Fastest path: Submit a medical necessity appeal through your Blue Cross Blue Shield plan&

Do You Qualify for Zanzalintinib (XL092) Coverage by Humana in Ohio? Decision Tree & Appeal Guide

Answer Box: Your Path to Coverage Zanzalintinib (XL092) is investigational and typically not covered by Humana Medicare Advantage outside clinical trials. However, you can pursue coverage through: 1. Check clinical trial eligibility first—trials cover routine care costs 2. Request formal coverage determination using Humana's Medicare Part D

Getting Zanzalintinib (XL092) Covered by Cigna in California: Clinical Trial Access, Compassionate Use, and Appeals Guide

Answer Box: How to Get Zanzalintinib (XL092) Coverage Zanzalintinib (XL092) is investigational and not FDA-approved, making direct Cigna coverage extremely rare. Your fastest path to access: 1. Check clinical trial eligibility on ClinicalTrials.gov (search "XL092" or "zanzalintinib") 2. If no suitable trial, request Exelixis compassionate

How to Get Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Virginia: Clinical Trial Access and Compassionate Use Guide

Answer Box: Getting Zanzalintinib (XL092) Coverage in Virginia Zanzalintinib (XL092) is not FDA-approved and typically isn't covered by Blue Cross Blue Shield Virginia outside clinical trials. Your fastest path: 1) Check ClinicalTrials.gov for ongoing STELLAR program studies, 2) Contact Exelixis directly about compassionate use programs, and 3)

Work With Your Doctor to Get Zanzalintinib (XL092) Covered by Cigna in Ohio: Complete Approval Guide

Answer Box: Getting Zanzalintinib (XL092) Covered by Cigna in Ohio Zanzalintinib (XL092) is investigational and not FDA-approved, so Cigna typically won't cover it outside clinical trials. Your fastest path is through Exelixis's compassionate use program combined with a prior authorization appeal. Start by having your oncologist

How to Get Zanzalintinib (XL092) Covered by Blue Cross Blue Shield in Illinois: Complete Appeals Guide for Investigational Cancer Drugs

Answer Box: Getting Zanzalintinib (XL092) Covered in Illinois Zanzalintinib (XL092) is investigational and typically excluded from Blue Cross Blue Shield of Illinois coverage. Your fastest path: 1) Apply for Exelixis expanded access program (free drug, 30-60 days), 2) Submit prior authorization with robust medical necessity documentation, and 3) If denied,